Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
LSPGBL
- Development stage
- Preclinical
- Lead developer
- Sathgen Therapeutics
- Modality
- Small Molecules
01
Overview
LSPGBL is a preclinical-stage small molecule therapeutic being developed by Sathgen Therapeutics, a subsidiary of Godavari Biorefineries Ltd (GBL). The drug is part of the company's Lead Small molecule Program (LSP) and is designed to target cancer stem cells (CSCs), which are often resistant to conventional therapies and are primarily responsible for tumor recurrence and metastasis. LSPGBL is being evaluated for a broad range of oncological indications, including breast cancer, prostate cancer, oral cancer, glioblastoma (GBM), hepatic cancer, cervical cancer, colon cancer, and lung cancer. As of 2023, the program remains in the preclinical phase of development, with research focused on assessing its efficacy and safety across multiple solid tumor models.
Beyond the preview
Go deeper on LSPGBL.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on LSPGBL.